Quick Answer
Neuphoria Therapeutics Inc. reported Revenue (ASC 606) of $15.65 million for fiscal year 2025.
Neuphoria Therapeutics Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $15.65M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| March 31, 2025 | $15.00M | — | +2163.4% |
| December 31, 2024 | $662.7K | — | — |
- The most recent figure is from Neuphoria Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: